Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 12/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.51 |
| ▸ | POLRMT | O00411 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17522701 | 0.91 | P2RY2 (0.45) | P2RY2P2RY4POLRMTPOLA1P2RX1 | |
| SCHEMBL17124611 | 0.88 | P2RY2 (0.42) | P2RY2P2RY4POLRMTPOLA1P2RX1 | |
| SCHEMBL3699139 | 0.88 | POLRMT (0.55) | P2RY2P2RY4POLRMTP2RX1P2RX3 | |
| SCHEMBL16710862 | 0.88 | POLRMT (0.55) | P2RY2P2RY4POLRMTP2RX1P2RX3 | |
| SCHEMBL13519829 | 0.88 | POLRMT (0.55) | P2RY2P2RY4POLRMTP2RX1P2RX3 | |
| SCHEMBL3696204 | 0.85 | POLRMT (0.52) | P2RY2P2RY4POLRMTP2RX1P2RX3 | |
| SCHEMBL10120066 | 0.80 | P2RY2 (0.41) | P2RY2P2RY4POLRMTP2RX1P2RX3 | |
| SCHEMBL4763052 | 0.80 | P2RY2 (0.47) | P2RY2P2RY4POLRMTP2RX1P2RX3 | |
| SCHEMBL15682895 | 0.79 | POLRMT (0.55) | P2RY2P2RY4POLRMTP2RX1P2RX3 | |
| SCHEMBL12254003 | 0.79 | P2RY2 (0.45) | P2RY2P2RY4POLRMTP2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501699-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-08-06 | — | — | US | disclosed |
| US-8415309-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGMENT PTY LTD (AT) | 2013-04-09 | — | — | US | disclosed |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8119607-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-21 | — | — | US | disclosed |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | P2RY2 202/4885P2RY4 173/4885POLRMT 54/4885 |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | P2RY2 202/4885P2RY4 173/4885POLRMT 54/4885 |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | P2RY2 202/4885P2RY4 173/4885POLRMT 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.